Whether you like them or not, weight-loss drugs have changed the world. Obesity levels in the US, which had been on the rise for years,

Backed by a $10 million investment in manufacturing tech, Langers Juice is looking to play a bigger role in the growing functional beverage boom.

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Epidemiological evidence indicates that MASLD is associated with an increased

This narrative review discusses the current landscape of glucagon-like peptide-1 therapies in the context of alcohol and other substance use disorders, mental health considerations, and

Fiber is resurging in snacks as interest in gut health, GLP-1 use and clean-label demand grow, pushing brands to rethink functional nutrition beyond protein.

Structure Therapeutics CEO Ray Stevens talked about the biotech’s path forward and his expectations for the future of the booming GLP-1 space.

(NaturalNews) Introduction: The High Cost of Quick FixesIn the frenzied pursuit of rapid weight loss, millions have turned to GLP-1 drugs like Ozempic and Wegovy,…

Publication date: February 2026 Source: Journal of Functional Foods, Volume 137 Author(s): Chiao-Wei Lin, Hsin-Bai Zou, Rou-An Chen, Chi-Shan Li, Chia-Ying Lin, Cheng-Chih Hsu

Post Content

NEW YORK, Jan. 21, 2026 /PRNewswire/ — Matthew DelMauro, MD, board-certified plastic surgeon, is reporting a noticeable increase in patients seeking plastic surgery after significant

Novo Nordisk’s ‘There’s Only One Ozempic’ campaign is about reasserting the drugmaker’s brand name in an increasingly competitive landscape. Ozempic-maker Novo Nordisk turned to the

ABSTRACT Background GLP-1 receptor agonists (GLP-1) and dual GLP-1/gastric inhibitory polypeptide (GIP) agonists emerged in recent years to promote weight loss. By reducing subcutaneous fat,

Who says pharma can’t have personality? Ozempic leans into humor with a familiar duo, Justin Long and John Hodgman from the ‘Mac VS PC’ era.

Justin Long and John Hodgman this time represent, respectively, Novo Nordisk’s original GLP-1, Ozempic, vs. “other GLP-1 products for type 2 diabetes.”

What You Should Know – Vida Health has partnered with RxSaveCard to launch Vida Self-Pay, a first-of-its-kind platform that bypasses traditional PBM markups for anti-obesity

A new financial report claims weight loss drugs like Ozempic and Wegovy could deliver an unexpected beneficiary: the airline industry. According to a study from

Key Points Novo Nordisk just launched an oral version of its popular weight-loss therapy, Wegovy. This move might help it make some headway in an

Nearly 2.2 million patients were prescribed a GLP-1 RA between January 2019 and December 2025, according to the study.

This study examines the prescribing of glucagon-like peptide-1 receptor agonists for adolescents with obesity and associated disparities.

This comparative effectiveness research study examines whether kidney outcomes differ with sodium-glucose cotransporter-2 (SGLT2) inhibitor vs glucagon-like peptide-1 (GLP-1) receptor agonist treatment in individuals with

People with type 2 diabetes taking glucagon-like peptide-1 (GLP-1) receptor agonists were more likely to develop chronic cough than people using other second-line medications, a

Novo Nordisk is worried about competition and wants to be seen as the cool kid… by using a 20-year-old ad format.

Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded

The drugmaker is reprising an Apple campaign with Justin Long and John Hodgman to highlight Ozempic’s FDA-approved uses Drugmaker Novo Nordisk is running ads that

Ozempic isn’t just slimming waistlines—it may be trimming jet fuel bills, too. A new analysis from financial firm Jefferies estimates that if GLP-1 weight loss

SAN FRANCISCO–(BUSINESS WIRE)–Vida Health today announced the launch of Vida Self-Pay (Powered by RxSaveCard) to help employers reduce prescription drug costs.

These medications “don’t magically fix weight loss”, he said

Coca-Cola chairman and CEO James Quincey joins ‘Squawk Box’ to discuss the state of the consumer, impact of tariffs, impact of GLP-1 drugs on the

It’s Tuesday, January 20. This is The Front Page, your daily window into the world of The Free Press—and our take on the world at

Dulaglutide, a long-acting GLP-1 receptor agonist, can suppress copeptin levels in individuals with euvolaemia, a secondary analysis of two clinical trials shows. Medscape News UK

Discontinuing the use of GLP-1 weight-loss medications triggers weight regain more than previously thought, a new study suggested. The research, which was published in The

Weight Watchers’ new CMO on the brand’s reinvention, GLP-1 direction and ChatGPT launch  Ad Age

ABSTRACT Background Pharmacotherapy offers a potential solution for individuals with overweight and obesity to decrease their body weight. However, there is limited knowledge of the

On 20 January 2025, Donald Trump returned to the White House for a second term. It’s been politically divisive and visually rich. 12 months on,

Post Content

Abstract Aim To quantify the relative importance of frequency of administration in basal insulin treatment preferences of people living with type 2 diabetes (T2D) in